Omnibus VIII Regulation: A New Era of Cosmetic Safety in the EU

Omnibus VIII Regulation: A New Era of Cosmetic Safety in the European Union

Understanding EU Regulation 2026/78 and Its Impact on the Cosmetics Industry

Introduction

The European Union has long been at the forefront of consumer safety, particularly in the cosmetics sector. Omnibus VIII Regulation (EU 2026/78) represents the latest step in this ongoing commitment, introducing significant changes to how cosmetic ingredients are regulated across member states. This regulation, which takes effect on May 1, 2026, marks a critical evolution in the EU’s approach to protecting consumers from potentially harmful substances in cosmetic products.

What is Omnibus VIII Regulation?

Omnibus VIII (Regulation EU 2026/78) is an amendment to the fundamental Cosmetics Regulation (EC) No 1223/2009. The regulation specifically targets CMR substances—those classified as carcinogenic, mutagenic, or toxic to reproduction—introducing new bans and restrictions on their use in cosmetic products sold throughout the European Union.

This regulation follows the EU’s established pattern of aligning cosmetics legislation with updated hazard classifications under the CLP Regulation (Classification, Labelling and Packaging).

Implementation Timeline and Application Date

The regulation’s timeline is notably aggressive compared to previous amendments. Omnibus VIII entered into force in January 2026 and will apply across all EU member states from May 1, 2026. Critically, there are no exceptions or adaptation periods—a departure from typical regulatory transitions that usually allow 12 months or more for market adjustment.

This strict deadline reflects the EU’s precautionary approach to CMR substances. From May 1, 2026, all non-compliant cosmetic products must be removed from the EU market, regardless of whether they are already on retail shelves or in distribution channels. This creates significant pressure on cosmetics companies to reformulate products and clear existing inventory well before the compliance date.

Key Amendments and Affected Substances

Omnibus VIII amends Annexes II through V of the Cosmetics Regulation, which govern prohibited substances and substances permitted only under specific restrictions. The changes affect a range of commonly used cosmetic ingredients, requiring manufacturers to either reformulate products or ensure compliance with new concentration limits.

Silver Powder

Silver powder now faces regulation based on particle size. When used in toothpaste and mouthwash, it is restricted to a maximum concentration of 0.05%. This size-dependent approach reflects growing scientific understanding of how nanoparticles and microparticles interact differently with human tissue.

CI 77820 (Color Additive)

Similar to silver powder, CI 77820 is now regulated based on particle size. When particles measure between 100 nanometers and 1 millimeter, the substance is permitted in lip products and eye shadows at concentrations up to 0.2%. This nuanced regulation demonstrates the EU’s sophisticated approach to ingredient safety.

Newly Banned Substances

Several substances face outright bans under Omnibus VIII:

Sodium perborate, commonly used as a bleaching agent in cosmetic formulations, is now prohibited due to its CMR classification.

Multi-walled carbon nanotubes, despite their innovative applications in cosmetics, are banned due to safety concerns related to their structure and potential toxicity.

Acetone oxime, used in various formulations, also faces prohibition under the new regulation.

Hexyl Salicylate: A Case Study in Graduated Restrictions

Perhaps the most impactful change in Omnibus VIII concerns hexyl salicylate, a widely used fragrance compound found in countless cosmetic products. The regulation introduces a complex framework of concentration limits that vary by product type and intended user age, reflecting the substance’s CMR Category 2 classification.

Inhalation and Impurity Concerns

Beyond concentration limits, Omnibus VIII addresses other safety concerns related to hexyl salicylate:

The substance is not applicable to any sprayable product, including mouth spray, that may lead to exposure through inhalation. This restriction acknowledges the different risk profile associated with inhaled versus topically applied substances.

If salicylic acid appears as an impurity from the breakdown of hexyl salicylate, it must be maintained at a technically unavoidable trace level. This requirement stems from the fact that salicylic acid itself is not permitted in products for children under three years of age.

Why Omnibus VIII Matters

Omnibus VIII represents more than just another regulatory update—it embodies the EU’s evolving philosophy toward cosmetic safety and consumer protection. Several aspects of this regulation deserve particular attention:

Particle Size as a Safety Factor

The regulation’s focus on particle size, particularly regarding silver powder and CI 77820, illustrates the EU’s sophisticated understanding of how materials behave differently at different scales. Nanoparticles and microparticles can have substantially different toxicological profiles than their bulk counterparts, a reality that Omnibus VIII explicitly acknowledges through its size-dependent restrictions.

Consolidation of CMR Strategy

Omnibus VIII consolidates the European strategy to eliminate or severely restrict all CMR substances from cosmetic products. This represents a precautionary approach to consumer safety that prioritizes the avoidance of potential long-term health effects, even when immediate risks may appear minimal.

No Grace Period for Compliance

Unlike other cosmetic amendments that typically provide a year or more to clear non-compliant stock from shelves, CMR bans under Omnibus VIII are stricter. The requirement to remove all non-compliant products by May 1, 2026—regardless of when they entered the market—underscores the seriousness with which the EU views CMR-related risks.

Impact on the Cosmetics Industry

The implementation of Omnibus VIII creates significant operational challenges for cosmetics manufacturers, distributors, and retailers operating in the EU market.

Reformulation Requirements

Companies must reformulate products containing banned substances or substances exceeding new concentration limits. For hexyl salicylate, which appears in fragrance formulations across countless product lines, this may require extensive reformulation efforts. Perfumers must identify alternative fragrance compounds that can replicate desired scent profiles while maintaining product stability and consumer acceptance.

Safety Assessment Updates

Many cosmetic products on the EU market that might have recently undergone safety assessments may no longer be compliant with the latest provisions. Companies must review existing safety assessments and potentially commission new evaluations for reformulated products. This creates additional costs and regulatory burden, particularly for smaller manufacturers.

Immediate Action Items

Cosmetics companies should prioritize several immediate actions to ensure compliance by the May 1, 2026 deadline:

• Conduct comprehensive fragrance reviews across all product lines to identify hexyl salicylate content and assess compliance with new concentration limits.
• Review silver-containing products, particularly oral care items, to verify particle size specifications and ensure concentration compliance.
• Audit color cosmetics containing CI 77820 to confirm particle size distributions and concentration levels in lip and eye products.
• Check preservative systems for affected substances, particularly o-phenylphenol and derivatives, which face updated restrictions under Annex V.
• Eliminate products containing sodium perborate, multi-walled carbon nanotubes, and acetone oxime from formulations and clear existing inventory before the compliance date.

Supply Chain Considerations

The tight implementation timeline creates particular challenges for global cosmetics companies with complex supply chains. Products manufactured outside the EU but destined for European markets must comply with Omnibus VIII from May 1, 2026. Companies must coordinate with international suppliers to ensure ingredient specifications meet the new requirements, potentially requiring supply chain audits and raw material testing programs.

Omnibus VIII in Broader Context

Omnibus VIII does not exist in isolation but rather represents one element in the EU’s comprehensive approach to chemical safety and consumer protection. The regulation aligns with broader European initiatives such as the Chemicals Strategy for Sustainability, which aims to ensure a toxic-free environment and promote the safe and sustainable use of chemicals.

The regulation also demonstrates the EU’s continuing influence on global cosmetics standards. While Omnibus VIII specifically applies only to products sold in the EU market, many multinational cosmetics companies choose to harmonize their global formulations with EU requirements rather than maintaining separate product versions for different markets. This regulatory phenomenon—often called the “Brussels Effect”—means that EU cosmetics regulations frequently set de facto global standards.

Looking Forward

Omnibus VIII will not be the final word on cosmetic ingredient safety. The regulation explicitly builds on the 21st Adaptation to Technical Progress under the CLP Regulation, and future adaptations will inevitably bring additional updates to cosmetic ingredient restrictions. Companies operating in the EU market should anticipate that the regulatory landscape will continue to evolve as scientific understanding of ingredient safety develops.

Furthermore, the EU’s focus on CMR substances in cosmetics may expand to other categories of concern, such as endocrine disruptors, persistent organic pollutants, or substances with environmental impacts. The precautionary principle that underlies Omnibus VIII suggests that regulatory authorities will continue to err on the side of caution when scientific evidence raises questions about ingredient safety.

Conclusion

Omnibus VIII Regulation represents a significant milestone in EU cosmetics regulation, introducing comprehensive restrictions on CMR substances while demonstrating the regulatory sophistication necessary to address complex safety issues such as particle size effects and age-specific vulnerabilities. The regulation’s strict implementation timeline and elimination of grace periods for CMR substances underscore the EU’s commitment to prioritizing consumer safety over industry convenience.

For cosmetics companies, Omnibus VIII demands immediate attention and decisive action. The May 1, 2026 compliance deadline allows limited time for reformulation, safety reassessment, and inventory management. Companies that act proactively—conducting thorough ingredient reviews, engaging with suppliers, and initiating reformulation projects—will be best positioned to navigate this regulatory transition successfully.

Ultimately, Omnibus VIII reflects the EU’s conviction that consumers deserve the highest standards of safety in the products they use daily. While the regulation creates challenges for industry, it advances the fundamental goal of ensuring that cosmetics enhance consumer wellbeing without exposing them to unnecessary risks. As the cosmetics industry adapts to these new requirements, consumers can feel confident that the products available in the EU market meet rigorous safety standards informed by the latest scientific knowledge.

Here’s a detailed breakdown of the key Omnibus VIII (Commission Regulation (EU) 2026/78) substance changes

Annex III / IV / V substances with concentration limits

Substance (INCI / Name)	CAS	Annex change	Scope / product types	Max concentration (ready-to-use)	Key conditions / warnings
Silver (powder) (CI 77820), 100 nm < particle diameter < 1 mm	7440-22-4	Annex IV (colorant) – entry 142	(a) Lip products; (b) Eye shadow	0.2%	Only this particle-size fraction permitted as colorant under these uses/limits.
Silver (powder) (micron-sized), 100 nm < particle diameter < 1 mm	7440-22-4	Annex III (restricted) – entry 379	(a) Toothpaste; (b) Mouthwash	0.05%	Restricted to these oral product types and limit.
Hexyl Salicylate (Hexyl 2-hydroxybenzoate)	6259-76-3	Annex III (restricted) – entry 380	(a) Hydroalcoholic fragrances (except for <3y)	2.0%	Special additional rule for products intended for children <3 years.
			(b) All rinse-off (except specific child <3y categories)	0.5%
			(c) All leave-on (except specific child <3y categories)	0.3%
			(d) Toothpaste	0.001%
			(e) Mouthwash	0.001%
			(f) Products intended for children <3 years (listed categories in Annex entry)	0.1%	Not to be used for children <3 except toothpaste and the listed (f) product categories
o-Phenylphenol (Biphenyl-2-ol / 2-phenylphenol)	90-43-7	Annex V (preservative) – entry 7	(a) Rinse-off	0.2% (as phenol)	Not for applications leading to inhalation exposure; not for oral products; warning: “Avoid contact with eyes.”
Sodium o-Phenylphenate (Sodium 2-biphenylate)	132-27-4	Annex V (preservative) – entry 7	(b) Leave-on	0.15% (as phenol)	Combined use with o-Phenylphenol must not exceed the same limits (0.2% rinse-off / 0.15% leave-on). Same prohibitions/warning.

 

Annex II

Substance	CAS	Annex	Notes
Silver (nano) (1 nm < particle diameter ≤ 100 nm)	7440-22-4	Annex II (entry 1727 amended)	Nano silver is treated as prohibited.
Silver (massive) (particle diameter ≥ 1 mm)	7440-22-4	Annex II (entry 1727 amended)	Massive form included in prohibition language.
N,N’-Methylenediacrylamide	110-26-9	Annex II	Listed among newly prohibited substances in industry summaries; CAS confirmed in ECHA dossier.
Sodium 3-(allyloxy)-2-hydroxypropanesulphonate	52556-42-0	Annex II	Listed among newly prohibited substances; CAS confirmed in ECHA substance identity.